作者 | 张祖盛创新药如何规避马库什专利？本文简单介绍了EGFR、三代EGFR抑制剂和侵权判断理论，并以阿美替尼和拉泽替尼是否侵犯奥希替尼化合物专利为例，详细说明了如何进行药品化合物专利规避。01EGFR结构、与肿瘤关系肿瘤和表皮生长因子受体（epi ...
Activating mutations in EGFR are characteristic of patients with lung cancer who have high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. The randomized IPASS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback